<DOC>
	<DOCNO>NCT02043314</DOCNO>
	<brief_summary>The recommended treatment latent tuberculosis infection adult daily dose isoniazid 300mg 6 month . In Brazil , isoniazid formulate 100 mg table . The treatment duration high pill burden compromise patient adherence treatment . The Brazilian National Programme Tuberculosis request development new 300mg isoniazid formulation . The aim study compare bioavailability isoniazid 300mg new formulation three 100mg tablet reference formulation . The study randomize , single dose , open label , fast , two-phase crossover bioequivalence study wash period 7 day ( &gt; 7 half-life ) 28 healthy human volunteer . For determination isoniazid human plasma , investigator develop validated sensitive , simple rapid HPLC-MS/MS method . This support strategy adopt Brazilian National Program Tuberculosis treatment latent tuberculosis . The new formulation increase patient ' adherence treatment quality life . Medical doctor Brazil become aware new formulation new treatment strategy order prescribe right medication avoid error could result high frequency adverse event . Future research study evaluate pharmacovigilance , acceptability new tablet formulation impact cure rate .</brief_summary>
	<brief_title>A Bioequivalence Study Two Different Dosages Isoniazid Tablet Formulations Human Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>healthy men woman age 18 50 year BMI 18.5 29.9 kg/mÂ²</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>